HealthyAging

LATEST NEWS: Epitracker uncovers groundbreaking science that may help delay aging in dolphins and humans. Read our press release and the PNAS paper.

EPITRACKER HEALTHY AGING & LONGEVITY PROGRAM

Epitracker aims to help people live longer and healthier. Our Healthy Aging and Longevity Program has discovered approximately one hundred promising molecules, including our lead micronutrient, pentadecanoic acid (also called C15:0), to protect cells against age-driven degradation.

Today, C15:0 is being advanced through Epitracker's spinout health and wellness company, Seraphina Therapeutics, Inc., which recently raised $6.2M in Series A funding. Up next...ETI-1029 and ETI-1080, two promising natural compounds also being advanced to support healthy aging,

learn more about seraphina therapeutics

Our Recent Scientific Papers

C15:0 is a dietary saturated fatty acid with demonstrated efficacy treating multiple aging-associated conditions. Growing evidence supports that C15:0 may be the first essential fatty acid discovered in 90 years.

read OUR C15:0 discovery

Dolphins with low dietary intake and blood levels of C15:0 have a higher risk of having aging-associated conditions. When dolphins ate a higher fish-based C15:0 diet, aging-associated conditions, including chronic anemia, resolved.

Read our plos one paper

Epitracker analyzed an unprecedented 25-year longitudinal dolphin health dataset to successfully achieve a long-sought goal in the scientific aging community: clinically- relevant evidence of slow vs. accelerated aging individuals in the same population.

read our pnas paper

A library of promising molecules to improve our healthspan

Epitracker's Longevity Compound Library includes molecules that may help to detect, prevent, and treat key conditions that impair our longevity and quality of life, including:

Systemic inflammation
Anemia
Lipid peroxidation
Iron accumulation

Our molecules are also targeting gene expression within mammalian longevity genetic pathways and key hallmarks of aging, including cellular senescence, mitochondrial dysfunction, and impaired autophagy.

C15:0 to stem aging-related conditions

C15:0 is a dietary odd-chain saturated fatty acid targeting both clinical diseases and key hallmarks of aging.

Anemia of Inflammation

As we age, we are more likely to develop chronic, low-lying systemic inflammation and fragile red blood cells, which results in anemia of inflammation. Anemia of inflammation is the most common type of anemia in the elderly. An estimated 77% of people older than 85 years old have anemia of inflammation, which increases the risks of:

Falls
Longer hospital stays
More severe cardiovascular disease
Mortality

C15:0's anti-inflammatory and cell-protective activities have enabled C15:0 to effectively treat anemia of inflammation in multiple models.

C15:0 Efficacy

C15:0 has demonstrated repeatable efficacy across multiple models. C15:0 attenuated the following indices in models with disease:

Alleviated anemia (raised hemoglobin, hematocrit, and RBCs)
Lowered inflammation (lowered globulins, MCP-1, IL-6)
Lowered liver iron deposition in animal model for NASH
Reduced liver fibrosis severity in animal model for NASH
Lowered cholesterol, triglycerides, glucose and insulin

C15:0 Healthy Aging Mechanisms

Our studies to date support C15:0's healthy aging mechanisms, including:

Improved cell membrane integrity/resilience
Improved mitochondrial function
Upregulation of the AMP-activated protein kinase (AMPK) signaling pathway
AMPK activation (phosphorylation)
Predicted raised levels of geroprotective miRNA

C15:0 Cell-Based Activity

In human cell-based systems mimicking a variety of disease states, C15:0 has demonstrated significant dose-response anti-inflammatory and antifibrotic activity, including:

Lowered MCP-1 (a pro-inflammatory chemokine)
Lowered secreted immunoglobulin G
Lowered Collagen I
Lowered fibroblast proliferation

C15:0 Safety

C15:0 has a strong safety profile. To date, C15:0 has demonstrated no cytotoxicity (using 12 human cell systems at four concentrations) and no off-target effects (using 78 functional assays at 10 concentrations).

ETI-1029 and ETI-1080 for inflammaging

ETI-1029 is an amino acid that hat decreases with age in long-lived mammals. ETI-1029 is demonstrating mitochondrial protective and anti-inflammatory activities in human cell systems mimicking lipid peroxidation and inflammation. ETI-1029 significantly reduced macrophages, inflammatory cells that increase with age and have been proposed as a key players in inflammaging.

ETI-1080 is a xenobiotic that decreases with age in long-lived mammals. Higher blood levels of ETI-1080 are associated with lower glucose, cholesterol, triglycerides, insulin and liver enzymes; and higher red blood cells and hemoglobin.

As part of a planned Small Business Innovation Research (SBIR) project funded by the Office of Naval Research, Epitracker will be investigating the pharmacokinetics, activities and efficacies of ETI-1029 and ETI-1080 to better understand their potential as a means to prevent or treat inflammaging and other comorbidities of aging.

ETI-035 and ETI-059 for cachexia

ETI-035 and ETI-059 are being developed to treat aging-associated weakness and wasting of the body (cachexia) due to severe illness, poor appetite and cognitive impairment. ETI-035 and ETI-059 are partial cannabanoid 1 receptor (CNR1) agonists that may help increase appetite and cognitive function in the elderly.

In the News

Epitracker and Seraphina's groundbreaking discoveries to improve healthy aging and longevity are making a splash. Click below to see, read, and hear our most recent media coverage.